# Windham Venture Partners

> Windham Venture Partners is a VC fund backing Health Care and Medical. See 65 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 65
- Last investment: Jul 2026
- Lead investor: 12%
- Fund size: $100M
- Last fund: Aug 2014
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/windham-venture-partners/
- X (Twitter): https://www.twitter.com/windhamvp
- Website: http://www.windhamvp.com

Windham Venture Partners is a VC fund in New York focused on Health Care and Medical. Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology). Windham seeks to invest in and partner with companies that are commercializinggame-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors. For more information visit: www.windhamvp.com

## Contacts

5 contacts available for Windham Venture Partners. Shizune tracks 5 team members at Windham Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/windham-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.3M–$100M |
| Series B | $7M–$75M |
| Series C | $12M–$73M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 29 | 45% |
| Medical | 13 | 20% |
| Medical Device | 13 | 20% |
| Biotechnology | 11 | 17% |
| Health Diagnostics | 8 | 12% |

52 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 18 | 28% |
| Series C | 11 | 17% |
| Series A | 9 | 14% |
| Series D | 6 | 9% |
| Funding Round | 6 | 9% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 34 | 52% |
| Israel | 2 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adam Fine | Co-Founder, General Partner & CEO | 8 | https://shizune.co/investors/profile/adam-fine |
| Lorne Taichman | Director of Science & Technology | 0 | https://shizune.co/investors/profile/lorne-taichman-md-phd |
| Roger Fine | Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation | 0 | https://shizune.co/investors/profile/roger-fine |
| David J. Kereiakes | Managing Partner | 3 | https://shizune.co/investors/profile/david-j-kereiakes |
| Joe Proto | Venture Partner | 5 | https://shizune.co/investors/profile/joe-proto |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| PainTEQ | PainTEQ provides solutions and services to the interventional pain management community. |  | Venture - Series Unknown | Aug 27, 2025 |  |
| TailorMed | TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $27.5M | Series B | Nov 21, 2024 |  |
| TailorMed | TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $27.5M | Series B | Nov 21, 2024 |  |
| NeuSpera Medical | NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain | $23M | Series D | Jul 15, 2024 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $45M | Series C | Nov 21, 2023 |  |
| Revelle Aesthetics | Revelle Aesthetics features a team of the brightest and most passionate minds in the medical device and aesthetics industries. It was born from ExploraMed, a leading medtech incubator. | $30M | Venture - Series Unknown | Jun 01, 2023 |  |
| Clever Care Health Plan Inc. | Clever Care Health Plan is a healthcare company that offers medicare advantage health plans to its members. Clever Care Health Plan offers culturally sensitive health care solutions that provide members better access to the services they need, in the language they understand.The company was founded in 2019 and headquartered in Westminster,California with a second office in Arcadia, CA. | $42M | Series C | Mar 15, 2023 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M | Series B | Oct 25, 2022 |  |
| SubjectWell | SubjectWell is the risk-free clinical trials marketplace for patient recruitment | $35M | Series B | Oct 18, 2022 |  |

10 of 65 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 15 deals together
- [Vertex Ventures HC](https://shizune.co/investors/profile/vertex-ventures-hc) — VC Fund, 7 deals together
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 5 deals together
- [AV8 Ventures](https://shizune.co/investors/profile/av8-ventures) — VC Fund, 5 deals together
- [Figure 8 Investments](https://shizune.co/investors/profile/figure-eight-investments) — VC Fund, 4 deals together
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in Israel](https://shizune.co/investors/life-science-vc-funds-israel)
- [Life Science Investors in Middle East](https://shizune.co/investors/life-science-investors-middle-east)
- [Life Science VC Funds in Middle East](https://shizune.co/investors/life-science-vc-funds-middle-east)

## FAQ

### What does Windham Venture Partners invest in?

Windham Venture Partners invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Windham Venture Partners's check size?

Windham Venture Partners typically joins rounds of $4.3M–$100M at Series A, $7M–$75M at Series B and $12M–$73M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Windham Venture Partners participates in.

### How do I contact Windham Venture Partners?

Public channels for Windham Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Windham Venture Partners?

The team at Windham Venture Partners includes Adam Fine (Co-Founder, General Partner & CEO), Lorne Taichman (Director of Science & Technology) and Roger Fine (Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co